Evidence map›Paper›PMID 26352650›Full record

ReviewLiver international : official journal of the International Association for the Study of the Liver2016

Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis.

Basile Njei, Neil Gupta, Oforbuike Ewelukwa, Ivo Ditah, Munoh Foma, Joseph K Lim

Open access · greenAbstract readReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Review in Liver international : official journal of the International Association for the Study of the Liver, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Treatment and prevention of viral hepatitis in pregnancy.American journal of obstetrics and gynecology · 2022
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Mechanisms and Prevention of Vertical Transmission in Chronic Viral Hepatitis.Journal of clinical and translational hepatology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Basile NjeiSection of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA.
Neil GuptaSection of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA.
Oforbuike EwelukwaGastroenterology and Hepatology, University of Florida, Gainesville, FL, USA.
Ivo DitahGastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Munoh FomaDivision of Clinical Pathology, University of Yaounde 1, Yaounde, Cameroon.
Joseph K LimSection of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA.
Yale University · USMayo Clinic in Arizona · USUniversity of Florida · USUniversity Teaching Hospital of Yaounde · CMYale Cancer Center · US

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Training Program in Investigative HepatologyT32DK007356 · NIDDK · YALE UNIVERSITY · PI MICHAEL H NATHANSON · 1986 to 2026
$7.4M
NIDDK NIH HHS P30 DK034989NIDDK NIH HHS T32 DK007356
6 · The paper itself

Abstract

BACKGROUND &

aimsAntiviral drugs are safe and effective in the third trimester to prevent intrauterine transmission of hepatitis B virus, and are recommended for hepatitis B virus (HBV) infected gravid mothers (between weeks 28 and 32) with high viral load, followed by postnatal hepatitis B immunization in the newborn. We estimated the comparative efficacy of antiviral drugs for prevention of vertical transmission of HBV, through a network meta-analysis of clinical trials.

methodsWe conducted a comprehensive search of MEDLINE, EMBASE and published proceedings from major liver meetings from January 1980 to November 2014. We conducted pair-wise meta-analyses and Bayesian framework using Markov chain Monte Carlo methods, combining direct and indirect evidence for any given pair of treatments.

resultsSeventeen clinical trials involving 2764 newborns of hepatitis B surface antigen seropositive mothers were eligible for analysis. There were no clinical trials involving tenofovir or entecavir. On pair-wise meta-analyses, telbivudine (hazard ratio, HR 0.12, 95% confidence interval (CI) 0.04-0.37; I(2)  = 0%), and Lamivudine (HR 0.40, 95% CI 0.24-0.65; I(2)  = 0%), were more effective than placebo in reducing vertical transmission of HBV in high viremic hepatitis B e antigen (HBeAg)-positive chronic Hepatitis B Chinese patients. Sensitivity analyses limited to studies with HBeAg seropositive mothers revealed similar results.

conclusionsBased on a Bayesian network meta-analysis of clinical trials, combining direct and indirect treatment comparisons, telbivudine appears to be more effective than Lamivudine for preventing vertical transmission of HBV infection. Trials assessing the efficacy of tenofovir or entecavir compared to placebo or other antiviral drugs are lacking.

Indexed as

Antiviral AgentsFemaleHepatitis B, ChronicHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansInfant, NewbornInfectious Disease Transmission, VerticalPregnancyPregnancy Complications, InfectiousRandomized Controlled Trials as TopicTelbivudineThymidineViral LoadAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensTelbivudineThymidineantiviral therapyhepatitis Bvertical transmission

Identifiers

PMID26352650
PMCPMC4824664
OpenAlexW2130155272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.